Filing summary
Entity and period: The request identifies Solana Co, but the supplied filing is Helius Medical Technologies, Inc. (Nasdaq: HSDT), Form 10-K for the fiscal year ended December 31, 2022, filed March 9, 2023. The filing reports annual results; it does not provide a clear standalone Q4 financial summary.
Business context
Helius is a neurotechnology company commercializing PoNS, a non-implantable tongue-stimulation device used with supervised therapeutic exercise. U.S. marketing authorization covers gait deficit associated with mild-to-moderate MS in adults 22 and older. Canada authorizes PoNS for MS, mild-to-moderate traumatic brain injury balance deficit, and stroke-related gait deficit; Australia has authorized it for balance and gait, but the company reported no Australian commercial sales.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0.787 million | $0.522 million |
| Gross profit | $0.324 million; 41.2% gross margin | $0.224 million; 42.9% gross margin |
| Operating expenses | $15.840 million | $18.366 million |
| Operating loss | $15.516 million | $18.142 million |
| Net loss | $14.072 million | $18.132 million |
| Cash used in operating activities | $14.310 million | $13.388 million |
| Cash and cash equivalents at year-end | $14.549 million | $11.005 million |
| Working capital at year-end | $14.709 million | $9.941 million |
U.S. product sales were $0.318 million in 2022, following the April commercial launch; Canadian product sales were $0.460 million, down from $0.493 million. The company raised $18.0 million gross in an August 2022 equity-and-warrant offering and reported $17.869 million net cash from financing activities for the year. The offering materially increased shares outstanding. The filing does not identify conventional borrowings as a key funding source; it reports a $6.917 million derivative liability for the offering’s warrants at year-end. Total liabilities were $9.136 million, including that warrant liability.
Changes and unusual items
- Revenue rose 51% year over year, primarily reflecting the U.S. launch, while gross margin declined from 42.9% to 41.2%.
- Net loss narrowed by $4.060 million, partly because operating expenses fell and the company recorded $3.027 million of income from a decline in the fair value of warrant liabilities. This noncash valuation gain should be distinguished from operating performance.
- SG&A declined $1.536 million and R&D declined $1.728 million, as the company shifted focus toward U.S. commercialization and stock-based compensation decreased.
- A $0.757 million goodwill impairment reduced goodwill to zero. The company also recorded $0.834 million net interest expense, including offering costs allocated to the warrant liability, and a $0.756 million foreign-exchange loss.
Outlook, risks, and contingencies
Management said existing capital resources were expected to fund operations through 2023, but additional financing would be needed thereafter. Management and the auditor stated that recurring losses, limited revenue, and the need for additional working capital raise substantial doubt about the company’s ability to continue as a going concern. Management cautioned that financing may not be available on acceptable terms and that failure to secure it could require reduced operations or a wind-down.
- PoNS was not covered by Medicare or reimbursed by U.S. third-party payers at the time of the filing; management expected broad payer coverage to take at least 24 months. Self-pay patients were expected to be the primary U.S. sales source in the interim.
- Management planned to collect further clinical and real-world evidence, pursue unique reimbursement codes, and re-engage with CMS in 2023. A U.S. stroke trial was planned, subject to funding; enrollment in the PoNSTEP MS study began in the second half of 2022.
- The FDA had denied the company’s de novo request for the traumatic brain injury indication, citing insufficient evidence to separate the device’s contribution from physical therapy. Further development depended on obtaining nondilutive financing.
- Production delays, supply-chain constraints, labor shortages, limited market awareness, reliance on a single contract manufacturer, reimbursement uncertainty, competition, and the need for future capital are material risks.
- Nasdaq notified the company in September 2022 that its share price did not meet the $1 minimum bid requirement; the filing described a March 20, 2023 deadline to regain compliance.
- No litigation was disclosed that management believed would reasonably be expected to have a material adverse effect. The filing reported effective disclosure controls and management-assessed internal controls over financial reporting; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Confirm the entity: this source is Helius Medical Technologies, Inc., not Solana Co.
- Review subsequent filings for actual cash burn, financing, liquidity runway, and any developments affecting the going-concern assessment.
- Check progress on U.S. payer coverage, HCPCS coding, CMS discussions, and whether commercial sales convert beyond discounted or self-pay programs.
- Verify manufacturing capacity and delivery performance, clinical-study enrollment and outcomes, and regulatory progress for indications beyond MS.
- Assess dilution and potential warrant effects, including the terms and valuation of the 36 million public warrants and changes in shares outstanding.
- Check Nasdaq listing compliance and any subsequent notices or corporate actions.